Molecular targeted therapies for pancreatic cancer.

American Journal of Surgery
Daniel Borja-CachoSelwyn Maurice Vickers

Abstract

Pancreatic cancer cells express different mutations that increase the aggressiveness and confer resistance to conventional chemotherapy and radiotherapy. Molecules that selectively bind and inhibit these mutations are effective in other solid tumors and are now emerging as a complementary therapy in pancreatic cancer. The objective of this review is to describe the effect of drugs that inhibit specific mutations present in pancreatic cancer with special emphasis on clinical trials. We reviewed the English-language literature (MedLine) addressing the role of drugs that target mutations present in pancreatic cancer. Both preclinical and clinical studies were included. Preclinical evidence supports the combination of conventional approved therapies plus drugs that block epidermal growth factor receptor and vascular growth endothelial factor or induce apoptosis. However, most of the current clinical evidence is limited to small phase I trials evaluating the toxicity and safety of these regimens. The results of additional randomized trials that are still undergoing will clarify the role of these drugs in pancreatic cancer.

References

Jul 20, 1999·The Journal of Clinical Investigation·A AshkenaziR H Schwall
Aug 30, 2003·American Journal of Surgery·Sarah M Cowgill, Peter Muscarella
Nov 6, 2003·American Journal of Surgery·Alan J DurkinEmmanuel E Zervos
Dec 6, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fabrice DenisGilles Calais
Dec 16, 2003·American Journal of Surgery·Russell G Postier
Jan 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Udo VanhoeferJosé Baselga
Apr 13, 2004·Oncogene·Klaus-Michael Debatin, Peter H Krammer
Jul 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry Q XiongJames L Abbruzzese
Jul 23, 2004·The New England Journal of Medicine·David CunninghamEric Van Cutsem
Sep 1, 2004·The Lancet Oncology·Mary J MacKenzie
Sep 29, 2004·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Michael Baumann, Mechthild Krause
Dec 9, 2004·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·J Pablo ArnolettiSelwyn M Vickers
Dec 30, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hiroshi KuraharaTakashi Aikou
May 14, 2005·CA: a Cancer Journal for Clinicians·Irene M GhobrialAlex A Adjei
Nov 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hedy L KindlerEverett E Vokes
Jan 7, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lillian L SiuMalcolm J Moore
Feb 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian G CzitoHerbert I Hurwitz
Mar 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher H CraneRobert A Wolff
Mar 7, 2006·Cytokine & Growth Factor Reviews·Keping XieSuyun Huang
Mar 15, 2006·American Journal of Surgery·Sergio HuertaEdward H Livingston
Apr 13, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marta HamiltonPablo J Cagnoni
May 26, 2006·Nature·Reuben J Shaw, Lewis C Cantley
Jun 29, 2006·Alimentary Pharmacology & Therapeutics·Y H ShaibH B El-Serag
Jul 22, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eunice L KwakDaphne W Bell
Aug 18, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kenjiro KimuraKosei Hirakawa
Aug 22, 2006·American Journal of Surgery·Mohamad A EloubeidiSelwyn M Vickers

❮ Previous
Next ❯

Citations

Aug 4, 2011·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Israel VlodavskyMichael Elkin
Mar 31, 2011·Cancer Research·Amichay MeirovitzMichael Elkin
Feb 26, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Srinivas Reddy BoreddySanjay K Srivastava
Mar 4, 2010·The AAPS Journal·Jing LiJessie L-S Au
Sep 10, 2011·International Journal of Nanomedicine·Cornel Iancu, Lucian Mocan
Aug 19, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Lin ChenShuchun Luo
Sep 1, 2015·International Journal of Oncology·Ramadevi SubramaniRajkumar Lakshmanaswamy
Nov 26, 2010·The Mount Sinai Journal of Medicine, New York·Soley Bayraktar, Caio M Rocha-Lima
Mar 26, 2011·Journal of Cellular Physiology·Morena d'AveniaMaria Pascale
Sep 19, 2014·Journal of Clinical Pathology·Noor Azela Abdullah ThaniHarcharan K Rooprai
Sep 13, 2013·British Journal of Pharmacology·C GüngörM Bockhorn
Jun 24, 2017·International Journal of Molecular Sciences·Aleksandra AdamskaMarco Falasca
Apr 16, 2010·Expert Opinion on Therapeutic Targets·Elodie Ristorcelli, Dominique Lombardo
Feb 15, 2020·IUBMB Life·Fatemeh SadoughiSeyyed Mehdi Mirhashemi
Sep 1, 2009·Expert Review of Clinical Pharmacology·Jia LiMuhammad W Saif
Oct 26, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Özge ErSanti Nonell
Apr 10, 2016·Journal of Labelled Compounds & Radiopharmaceuticals·Fatma Yurt LambrechtCagla Kayabası
Oct 15, 2020·Cancer Science·Naruomi JinnoHiromi Kataoka

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

British Medical Bulletin
S A DanoviN R Lemoine
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
Axel KleespiesChristiane J Bruns
© 2022 Meta ULC. All rights reserved